- MNTA presented at Canaccord Genuity conference on 8/10/2011.
- My quick notes are below. Check the blog for more detailed notes from other recent events including the 2q2011 conference call and the 8/17/11 webcast at Wedbush (coming soon)
- "We will not try to be the first biosimilar approved by FDA, but will try to get first interchangeable biogeneric approved"
- M118 - have been in discussions with potential partners, but this is not an easy area to partner. We continue to believe the drug is partnerable and is good product with high potential
- M402 - hoping for IND submission in 2011 [language around this program is continuously less bullish and timeline continues to slip]
- Generic lovenox supply chain: heparin from China, processed by sandoz in Austria and API fill/finish.
- q&a was in beakout session and not webcast
Your support is greatly appreciated